The Crossover strategy launched in April 2018, completing Sofinnova's investment platform by enabling it to invest across the life-sciences value chain, from seed stage to later-stage.
We invest across all biotech sectors, focusing on companies with game-changing science that has initial proof of concept.
|2018||Sofinnova Crossover I||€445 million|
Fund: Sofinnova Crossover I
AMT: €445 million
"Sometimes you need to have a significant stake in a company and be in the board room to really drive some of the strategy and the changes it may need."
"Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage development and proof of concept."
"It is exciting to help companies find that next gear of growth as they bring new medicines to market.”
"The science in Europe is the same quality as any you'll find in the U.S."
MD Start & Crossover
Capital & Crossover
Crossover & Industrial Biotech
Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintenance trial in ulcerative colitis
LimFlow raises $40 million (€36 million) in Series D financing
Redx nominates GI-targeted ROCK Inhibitor, RXC008, as clinical development candidate
Abivax reports promising ABX464 phase 2A one-year maintenance results in rheumatoid arthritis
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA